Successful exit in the specialty pharma sector

AMW GmbH was founded in Warngau in 2008 and specializes in the development and marketing of implants for controlled drug delivery (drug delivery systems). AMW GmbH's implants enable a delayed and more uniform release of active ingredients and thus contribute to a more effective and more tolerable absorption of therapeutic agents for the patient. In addition, the implants have sufficient drug depots for longer - in contrast to oral drug administration, daily intake is therefore not necessary.

The company currently has two approved implants, Goserelin and Leuprorelin, for the treatment of hormone-sensitive tumors, which are marketed worldwide both through direct sales and through out-licensing from renowned local and global pharmaceutical partners. AMW GmbH covers the entire value chain for its implants, from development and production to international marketing. The company also has a promising pipeline of other products for various indications.

"I would like to express my sincere gratitude to the Bayern Kapital team and all our investors who have supported our company with full commitment over the past years and contributed significantly to the successful development of AMW. At the same time, we are delighted to welcome our new partners. After another year of record sales in 2025, I look forward to continuing to grow with them and becoming a global leader in the development, manufacture and distribution of biodegradable controlled drug delivery systems," says Philipp Karbach, CEO and shareholder of AMW GmbH.

"Together with SHS Gesellschaft für Beteiligungsmanagement mbH, Bayern Kapital participated in the company's first financing round in 2009 as well as in several further financing rounds up to Series E. As an investor who has accompanied AMW GmbH from its first financing round through all phases of its entrepreneurial development to successful expansion and scaling, we are very proud of the company's success story. The company's biodegradable controlled-release implants address important gaps in the treatment of hormone-sensitive tumors and we are convinced that AMW GmbH, together with the new investors, is excellently positioned for further successful growth. We would like to thank Philipp Karbach and his team for their many years of trusting cooperation and wish them all the best for the future. I would also like to thank Dr. Martin Zügel and Manfred Ulmer-Weber for their close, constructive and trusting cooperation on the Advisory Board of AMW GmbH," says Monika Steger, Managing Director of Bayern Kapital.